Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: A 13-year experience

Liver Transplantation

Volumn 19, Issue 6, 2013, Pages 611-618

  Bohorquez, Humberto E ^a   Cohen, Ari J ^a   Girgrah, Nigel ^a   Bruce, David S ^a   Carmody, Ian C ^a   Joshi, Shoba ^a   Reichman, Trevor W ^a   Therapondos, George ^a   Mason, Andrew L ^b   Loss, George E ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN M; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE; TENOFOVIR; VIRUS DNA; HEPATITIS B CORE ANTIGEN; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; COMPLICATION; DONOR; FOLLOW UP; ISOLATION AND PURIFICATION; LIVER; LIVER FAILURE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TIME; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84878339856     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23644     Document Type: Article

References (38)

1. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10 (pt 2): 1003-1019.
2. Yu L, Koepsell T, Manhart L, Ioannou G,. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009; 15: 1343-1350.
3. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234.
4. de Villa VH, Chen YS, Chen CL,. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation 2003; 75 (suppl): S49-S53.
5. Merrill RM, Hunter BD,. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis 2011; 15: e78-e121.
6. Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142-146.
7. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494-499.
8. Prieto M,. Antibody to hepatitis B core antigen-positive grafts: not perfect but no longer marginal. Liver Transpl 2009; 15: 1164-1168.
9. Cholongitas E, Papatheodoridis GV, Burroughs AK,. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279.
10. Perrillo R,. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009; 15: 223-232.
11. Pondé RA, Cardoso DD, Ferro MO,. The underlying mechanisms for the 'anti-HBc alone' serological profile. Arch Virol 2010; 155: 149-158.
12. Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, et al. Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 2001; 15 (suppl 6): 55-58.
13. Loss GE Jr, Mason AL, Nair S, Blazek J, Farr G, Guo L, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003; 9: 1258-1264.
14. Laryea MA, Watt KD,. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl 2012; 18: 514-523.
15. Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593.
16. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R,. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103: 1649-1656.
17. Van Thiel DH, De Maria N, Colantoni A, Friedlander L,. Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 1999; 68: 519-522.
18. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV,. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93: 230-239.
19. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP,. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742.
20. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T,. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495.
21. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-1584.
22. Skagen CL, Jou JH, Said A,. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts-a systematic analysis. Clin Transplant 2011; 25: E243-E249.
23. Villeneuve E, Vincelette J, Villeneuve JP,. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 (suppl B): 59B-62B.
24. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN,. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314-320.
25. Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, et al. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther 2011; 16: 479-487.
26. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ,. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058-1061.
27. Habib S, Shaikh OS,. Hepatitis B immune globulin. Drugs Today (Barc) 2007; 43: 379-394.
28. Congly SE, Burak KW, Coffin CS,. Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. Expert Rev Clin Immunol 2011; 7: 429-436.
29. Saab S, Waterman B, Chi AC, Tong MJ,. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 2010; 16: 300-307.
30. Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D,. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl 2010; 16: 885-894.
31. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 27: 75:1179-1186.
32. Mutimer D,. Prevention of de novo hepatitis B virus infections: more seems no better. Liver Transpl 2010; 16: 256-258.
33. Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005; 37: 3187-3189.
34. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC,. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006; 6 (pt 1): 1077-1083.
35. Chang MS, Olsen SK, Pichardo EM, Heese S, Stiles JB, Abdelmessih R, et al. Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl 2012; 18: 834-838.
36. Prieto M, Gõmez MD, Berenguer M, Cõrdoba J, Rayõn JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7: 51-58.
37. Kim HY, Choi JY, Park CH, Song MJ, Jang JW, Chang UI, et al. Adult living donor liver transplantation using hepatitis B core antibody-positive grafts in Korea, a hepatitis B-endemic region. Gut Liver 2011; 5: 363-366.
38. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA,. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986; 83: 1627-1631.